387 related articles for article (PubMed ID: 26899451)
1. Mechanism of action of brexpiprazole: comparison with aripiprazole.
Stahl SM
CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
[TBL] [Abstract][Full Text] [Related]
2. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
Hope J; Castle D; Keks NA
Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
[TBL] [Abstract][Full Text] [Related]
3. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
Citrome L
Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of cariprazine.
Stahl SM
CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157
[TBL] [Abstract][Full Text] [Related]
5. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
[TBL] [Abstract][Full Text] [Related]
6. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors.
Ishima T; Futamura T; Ohgi Y; Yoshimi N; Kikuchi T; Hashimoto K
Eur Neuropsychopharmacol; 2015 Apr; 25(4):505-11. PubMed ID: 25687838
[TBL] [Abstract][Full Text] [Related]
8. Brexpiprazole (Rexulti) for schizophrenia and depression.
Med Lett Drugs Ther; 2015 Aug; 57(1475):116-8. PubMed ID: 26262883
[No Abstract] [Full Text] [Related]
9. Combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: A case report.
Fujiyama H; Sugawara H; Kanno T; Kawahara K; Tanaka H; Fukuhara R; Boku S; Takebayashi M
Psychiatry Clin Neurosci; 2020 Dec; 74(12):666-667. PubMed ID: 32909325
[No Abstract] [Full Text] [Related]
10. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole's receptor pharmacology and extrapyramidal side effects.
Poyurovsky M; Weizman R; Weizman A
Am J Psychiatry; 2008 Mar; 165(3):398; author reply 398-9. PubMed ID: 18316435
[No Abstract] [Full Text] [Related]
12. Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
Wood M; Reavill C
Expert Opin Investig Drugs; 2007 Jun; 16(6):771-5. PubMed ID: 17501690
[TBL] [Abstract][Full Text] [Related]
13. Brexpiprazole has a low risk of dopamine D
Amada N; Akazawa H; Ohgi Y; Maeda K; Sugino H; Kurahashi N; Kikuchi T; Futamura T
Neuropsychopharmacol Rep; 2019 Dec; 39(4):279-288. PubMed ID: 31487433
[TBL] [Abstract][Full Text] [Related]
14. Persistent hiccups associated with switching from risperidone to aripiprazole in a schizophrenic patient with cerebral palsy.
Yeh YW
Clin Neuropharmacol; 2011; 34(4):135-6. PubMed ID: 21768798
[TBL] [Abstract][Full Text] [Related]
15. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
Citrome L
Int J Clin Pract; 2015 Nov; 69(11):1211-20. PubMed ID: 26477545
[No Abstract] [Full Text] [Related]
16. A positron emission tomography occupancy study of brexpiprazole at dopamine D
Girgis RR; Forbes A; Abi-Dargham A; Slifstein M
Neuropsychopharmacology; 2020 Apr; 45(5):786-792. PubMed ID: 31847007
[TBL] [Abstract][Full Text] [Related]
17. Brexpiprazole for the treatment of schizophrenia.
Yee A
Expert Rev Neurother; 2016; 16(2):109-22. PubMed ID: 26650624
[TBL] [Abstract][Full Text] [Related]
18. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Citrome L; Stensbøl TB; Maeda K
Expert Rev Neurother; 2015 Oct; 15(10):1219-29. PubMed ID: 26402059
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
Kessler RM
Am J Psychiatry; 2007 Sep; 164(9):1310-2. PubMed ID: 17728411
[No Abstract] [Full Text] [Related]
20. [A new atypical antipsychotic with partial dopamine agonist effect (aripiprazole)].
Kerpel-Fronius S; Lóránt M
Neuropsychopharmacol Hung; 2004 Dec; 6(4):177-84. PubMed ID: 15825673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
